AstraZeneca’s (AZN) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research note released on Tuesday,Digital Look reports. The brokerage currently has a £175 price objective on the biopharmaceutical company’s stock.

Several other brokerages also recently commented on AZN. Berenberg Bank reiterated a “buy” rating and issued a £175 target price on shares of AstraZeneca in a report on Wednesday, October 7th. Royal Bank Of Canada restated an “outperform” rating and set a £145 price target on shares of AstraZeneca in a report on Tuesday, September 8th. Citigroup upped their price objective on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £117 price objective on shares of AstraZeneca in a research note on Tuesday, September 29th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of £153.57.

AstraZeneca Price Performance

Shares of LON:AZN opened at £129.80 on Tuesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The stock has a market cap of £201.31 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20. The stock’s fifty day simple moving average is £121.60 and its two-hundred day simple moving average is £130.60. AstraZeneca has a 1-year low of £114.04 and a 1-year high of £157.32.

Insider Buying and Selling at AstraZeneca

In related news, insider Michel Demare purchased 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average cost of £121.21 per share, with a total value of £303,025. Company insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.